- ►annals.org [PDF] R Raschke, J Hirsh, JR Guidry - Annals of internal medicine, 2003 - Am Coll Physicians Background: Site-specific validation of the activated partial thromboplastin
time (aPTT) therapeutic range is required to ensure administration of the
optimal dose of unfractionated heparin. Therapeutic ranges of 1.5 to 2.5 ... Cited by 41 - Related articles - BL Direct - All 5 versions
AN Nicolaides, MR Cesarone, G Laurora, MT De … - Angiology, 1999 - ang.sagepub.com DOI: 10.1177/000331979905001001 1999; 50; 781 Angiology Christopoulos, A.
Lennox, M. Malouf and G. Belcaro AN Nicolaides, MR Cesarone, G. Laurora, MT De
Sanctis, L. Incandela, A. Barsotti, M. Corsi, S. Vasdekis, D. Cited by 45 - Related articles - BL Direct - All 3 versions
JA Beckman, K Dunn, AA Sasahara, SZ … - Thrombosis and haemostasis, 2003 - ncbi.nlm.nih.gov Conventional anticoagulation for symptomatic pulmonary embolism consists of
continuous intravenous unfractionated heparin as a "bridge" to oral
anticoagulation. This strategy requires 5 days or more of intravenous ... Cited by 40 - Related articles - BL Direct - All 2 versions
GJ Merli - Advanced Studies in Medicine, 2002 - utasip.com There are more than 170 000 hospital admis- sions each year for deep vein
thrombosis (DVT) in the United States. Moreover, there are approxi- mately 90
000 readmissions for recurrent venous thromboembolic events, with an ... Related articles - All 6 versions
[CITATION] THE USE OF LOW MOLECULAR WEIGHT HEPARINS IN THE MANAGEMENT OF VENOUS …
J Harenberg, JA Scmidt, K Koppenhagen, A … - THROMBOSIS AND HAEMOSTASIS-STUTTGART-, 2000 - ma.uni-heidelberg.de Anticoagulation with heparin in patients with venous thromboembo- lism is well
established as the standard initial treatment. Unfractionated heparin (UFH) is
administered intravenously or subcutaneously, but re- quires dose ... Cited by 52 - Related articles - View as HTML - BL Direct - All 5 versions
RL Bick, BL Kaplan - European journal of medical research, 2004 - daignet.de Thrombosis is a common cause of death in the United States. Over two million
individuals die each year from an arterial or venous thrombosis or the
consequences thereof [1]. About an equal num- ber suffer non-fatal ... Cited by 6 - Related articles - View as HTML - BL Direct - All 4 versions
T Myrmel, TS Larsen, O Reikerås - Scandinavian Journal of Clinical & Laboratory …, 1992 - informahealthcare.com Eighteen patients admitted for implantation of a primary hip prosthesis were
randomized to one of the following thromboprophylactic regimens: (1) dextran 500
ml 12 h-' on the day of surgery and 500 ml on days 1, 3, and 5 post- ... Cited by 6 - Related articles - BL Direct - All 5 versions
P Lindmarker - Pathophysiology of Haemostasis and Thrombosis, 2000 - content.karger.com Studies have shown subcutaneous low- molecular-weight heparin (LMWH) to be at
least as safe and efficacious as intravenous unfractionated heparin (UFH) for
the treatment of venous thromboembolism (VTE). Furthermore, unlike UFH, ... Cited by 6 - Related articles - BL Direct - All 4 versions
EM Hylek, S Regan, LE Henault, M Gardner, … - Archives of Internal Medicine, 2003 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 35 - Related articles - BL Direct - All 4 versions
